A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month:
Biologics
Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.
Orthobiologics company Royal Biologics acquired the Fibrinet system from Vertical Spine Sept. 1.
Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release.
The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee.
Advertisement
The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement.
More than 6,000 members have joined the Biologic Association within the first six months of its website launch.
Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials:
Orthobiologics company Cerapedics received FDA approval to reduce the number of patients required for its P-15L bone graft clinical trial.
Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release.